¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Journal of interferon research."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® VDRL(venereal disease research laboratory) ÇÑ±Û ¼ºº´ ¿¬±¸½ÇÇè½Ç
¼³¸í   
  ¸Åµ¶±ÕÀÇ reagin¿¡ ´ëÇÑ Ç×ü. ¸Åµ¶ÀÇ ¼±º°°Ë»ç·Î »ç¿ëµÇ¸ç ¸Åµ¶ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ ¿©ºÎ¿Í Ä¡·áÈ¿°ú ÆÇÁ¤¿¡µµ »ç¿ëµÈ´Ù. ¸Åµ¶¿Ü¿¡µµ Àü½Å¼ºÈ«¹Ý¼º³¶Ã¢, ·ù¸¶Æ¼½º°üÀý¿° µî¿¡¼­µµ ¾ç¼ºÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¿µ¹® interferon ÇÑ±Û ÀÎÅÍÆä·Ð
¼³¸í   
  ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ µ¿¹°ÀÇ ¼¼Æ÷¿¡¼­ »ý»êµÇ´Â Ç×¹ÙÀÌ·¯½º¼º ´Ü¹éÁú. ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ Á¶Á÷ÀÌ »ý»êÇϴ Ç×¹ÙÀÌ·¯½º ÀÛ¿ëÀ̳ª Ç×Á¾¾çÀۿ렵ý¸®È°¼ºÀÌ Àִ ´ç´Ü¹éÁúÀ» ¸»ÇÑ´Ù. 1957³â ¿µ±¹ ±¹¸³ÀÇÇבּ¸¼ÒÀÇ A.¾ÆÀÌÀÛ½º¿Í J.¸°µç¸Õ¿¡ ÀÇÇØ ¾Ë·ÁÁ³´Ù. À̵éÀº ¿­Ã³¸®ÇÑ ¹ÙÀÌ·¯½º¸¦ ´Þ°¿ ³»¸·ÀÇ ¼¼Æ÷¿¡ Ã³¸®Çϰí ÇÏ·ç µ¿¾È ¹è¾çÇÑ ´ÙÀ½, ¹è¾ç¾×À» ÃßÃâÇÏ¿© »õ·Î¿î ´Þ°¿ ³»¸·°ú ¼¯Àº ÈÄ, »ì¾Æ Àִ ¹ÙÀÌ·¯½º¸¦ Áý¾î³ÖÀº °á°ú, ¹ÙÀÌ·¯½ºÀÇ ºÐ¿­ÀÌ ¾ïÁ¦µÇ¾ú°í, ±× ¹è¾ç¾×À» ³ÖÁö ¾ÊÀº °æ¿ì¿¡´Â ¹ÙÀÌ·¯½º°¡ ºÐ¿­µÇ¾î ¹ø½ÄÇÏ¿´´Ù. ÀÌ ½ÇÇèÀÇ Àǹ̴ ¹ÙÀÌ·¯½º°¡ µ¿¹°¼¼Æ÷¿¡ Ä§ÀÔÇϸ頹æ¾îÀÇ ±â´ÉÀ¸·Î ±× µ¿¹°¼¼Æ÷´Â ÀÎÅÍÆä·ÐÀ» »ý»êÇÏ¿© ¹ÙÀÌ·¯½ºÀÇ ºÐ¿­À» ¸·´Â´Ù´Â °ÍÀÌ´Ù. Á¦ÀÏ ¸¹ÀÌ ¿¬±¸µÈ ºÐ¾ß´Â Àΰ£ÀÇ ÀÎÅÍÆä·ÐÀÌ´Ù. ÀÎÅÍÆä·ÐÀº ¹ÙÀÌ·¯½º°¨¿° ¹× ³»µ¶¼Ò Åõ¿©, ³ª¾Æ°¡¼­´Â Ç׿øÀڱؠµî¿¡ ¹ÝÀÀÇÏ¿© °®°¡Áö ¼¼Æ÷·ÎºÎÅÍ ¹æÃâµÈ´Ù. IFNÀ̶ó°í ¾à±â. ÇöÀç, 3Á¾(IFN-¥á, IFN-¥â, IFN-¥ã)ÀÌ ¾Ë·ÁÁ® ÀÖÀ¸¸ç °¢°¢ ÀǾàǰÀ¸·Î »ç¿ëµÇ°í ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • journal
    1. ÇмúÁö 2. Àϱâ
  • research
    ¿¬±¸
  • research design
    ¿¬±¸°èȹ
  • research diagnostic criteria
    ¿¬±¸Áø´Ü±âÁØ
  • venereal disease research laboratory test
    ¸Åµ¶Ç÷û°Ë»ç, VDRL°Ë»ç
  • gamma interferon
    °¨¸¶ÀÎÅÍÆä·Ð
  • immune interferon
    ¸é¿ªÀÎÅÍÆä·Ð
  • interferon
    ÀÎÅÍÆä·Ð
  • interferon alpha
    ÀÎÅÍÆä·Ð¾ËÆÄ
  • interferon alpha-2b
    ÀÎÅÍÆä·Ð¾ËÆÄ-2b
  • interferon omega
    ÀÎÅÍÆä·Ð¿À¸Þ°¡
  • interferon receptor
    ÀÎÅÍÆä·Ð¼ö¿ëü
  • interferon tau
    ÀÎÅÍÆä·ÐŸ¿ì
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • journal
    1. ÇмúÁö, 2. Àϱâ
  • alpha-interferon
    ¾ËÆÄÀÎÅÍÆä·Ð
  • interferon
    ÀÎÅÍÆä·Ð
  • research
    ¿¬±¸
  • diagnostic research
    Áø´Ü¿¬±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • alpha-interferon
    ¾ËÆÄÀÎÅÍÆä·Ð
  • research diagnostic criteria
    ¿¬±¸Áø´Ü±âÁØ
  • research design
    ¿¬±¸°èȹ
  • gamma interferon
    °¨¸¶ÀÎÅÍÆä·Ð
  • interferon
    ÀÎÅÍÆä·Ð
  • immune interferon
    ¸é¿ªÀÎÅÍÆä·Ð
  • interferon receptor
    ÀÎÅÍÆä·Ð¼ö¿ëü
  • operational research
    ÀÛÀü¿¬±¸
  • research
    ¿¬±¸
  • venereal disease research laboratory test
    ¸Åµ¶Ç÷û°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immune interferon (Interferon-¥ã)
    ¸é¿ªÀÎÅÍÆä·Ð (°¨¸¶ÀÎÅÍÆä·Ð)
  • Lipid Research Clinic
    ÁöÁú¿¬±¸Áø·á¼Ò
  • RDC, see Research Diagnostic Criteria
    ¿¬±¸Áø´Ü±âÁØ, ¿¬±¸¿ë Áø´Ü±âÁØ
  • VDRL test= venereal disease research laboratory test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
  • VDRL test= venereal disease research laboratory test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immune interferon (Interferon-¥ã)
    ¸é¿ªÀÎÅÍÆä·Ð (°¨¸¶ÀÎÅÍÆä·Ð)
  • research diagnostic criteria(RDC)
    ¿¬±¸Áø´Ü±âÁØ
  • venereal disease research laboratory test =VDRL test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
  • venereal disease research laboratory test =VDRL test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
  • alpha (¥á)-interferon
    ¾ËÆÄÀÎÅÍÆä·Ð
  • beta (¥â)-interferon
    º£Å¸ÀÎÅÍÆä·Ð
  • gamma (¥ã) interferon
    °¨¸¶ÀÎÅÍÆä·Ð
  • interferon
    ÀÎÅÍÆä·Ð
  • interferon
    ÀÎÅÍÆä·Ð.
  • interferon
    ÀÎÅÍÆä·Ð
  • interferon (INF) gene
    ÀÎÅÍÆä·Ð À¯ÀüÀÚ
  • interferon (INF) receptor
    ÀÎÅÍÆä·Ð ¼ö¿ëü
  • interferon unit
    ÀÎÅÍÆä·Ð ´ÜÀ§
  • interferon, immune
    ¸é¿ªÀÎÅÍÆä·Ð (°¨¸¶ÀÎÅÍÆä·Ð)
  • interferon- a(ifn-a)
    ÀÎÅÍÆä·Ð a
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • interferon
    ÀÎÅÍÆä·Ð
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • interferon
    ÀÎÅÍÆä·Ð
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AJKD American Journal of Kidney Diseases
JOC Journal of Oncologic Clinical(?)
AEM Academic Emergency Medicine [journal]; analytical electron microscopy; ambulatory electrocardiograph...
AM Academic Medicine [journal]; actomyosin; acute myelofibrosis; adult male; adult monocyte; aerospace ...
BMJ bones, muscles, joints; British Medical Journal
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
JAMA Journal of the American Medical Association
NEJM New England Journal of Medicine
ARCI Addiction Research Center Inventory
AHCPR Agency for Health Care Policy and Research
AHRQ Agency for Health Care Research and Quality
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • JrId: 4848
    JournalTitle: Journal of interferon research.
    MedAbbr: J Interferon Res
    ISSN: 0197-8357
    ESSN:
    IsoAbbr: J. Interferon Res.
    NlmId: 8100396
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • interferon
    ÀÎÅÍÆä·Ð
    ¹ÙÀÌ·¯½ºÀÇ RNA¿Í ´Ü¹éÁú ÇÕ¼ºÀ» ¼±ÅÃÀûÀ¸·Î ¹æÇØÇÏ´Â Ç×¹ÙÀÌ·¯½º¼º ´Ü¹éÁúÀ» °üÀåÇÏ´Â ¼¼Æ÷ À¯ÀüÀÚÀÇ Àü»ç¿¡ ÀÇÇØ »ý¼ºµÈ ¹ÙÀÌ·¯½º ºñƯÀÌÀûÀÌ°í ¼÷ÁÖ Æ¯ÀÌÀû Ç×¹ÙÀÌ·¯½º ÀÛ¿ëÀ» ³ªÅ¸³»´Â ´ç´Ü¹éÁú ±ºÀÌ´Ù. ¶ÇÇÑ ÀÎÅÍÆä·ÐÀº ¸é¿ª Á¶Àý ±â´ÉÀ» °¡Áö¸ç ºñ¹ÙÀÌ·¯½º¼º ¼¼Æ÷³» ±â»ýüÀÇ ¼ºÀåÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖ´Ù. ¹ÙÀÌ·¯½º °¨¿°, ƯÈ÷ ÀÌÁß¼â RNA ¹ÙÀÌ·¯½º, ¼¼Æ÷³» ±â»ýü, ¿ø»ýµ¿¹°, ¼¼±Õ·ù ¹× ¼¼±Õ »ý»ê¹° µîÀÌ ÀÎÅÍÆä·ÐÀÇ »ý»êÀ» ÀÚ±ØÇÒ ¼ö ÀÖ´Ù. ÀÎÅÍÆä·ÐÀº »ý»ê ¼¼Æ÷¿Í ±â´É¿¡ µû¶ó 3±ºÀ¸·Î ³ª´©Áö¸¸ ¸ðµç µ¿¹° ¼¼Æ÷´Â ÀÎÅÍÆä·ÐÀ» »ý»êÇÒ ¼ö ÀÖ°í, ¾î¶² ¼¼Æ÷´Â ÇÑ Á¾·ù ÀÌ»óÀ» »ý»êÇÑ´Ù.
  • medical journal
    ÀÇÇÐÀâÁö, ÀÇÇÐÇмúÁö
  • clinical research
    ÀÓ»ó ¿¬±¸
  • pain research laboratory
    µ¿Åë ¿¬±¸¼Ò
  • preclinical research
    ÀÓ»ó Àü ¿¬±¸
  • research
    ¿¬±¸, Á¶»ç
  • The National Institute of Dental Research
    ±¹¸³ Ä¡ÀÇÇÐ ¿¬±¸¼Ò
  • VDRL : Venereal Disease Research LaboratoryÀÇ ¾àÀÚ. ¸Åµ¶±ÕÀÇ Reagin¿¡ ´ëÇÑ Ç×ü·Î, ¸Åµ¶ÀÇ ¼±º°°Ë»ç·Î »ç¿ëµÇ¸ç ¸Åµ¶ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ ¿©ºÎ°¡ Ä¡·á È¿°ú ÆÇÁ¤¿¡ »ç¿ëµÈ´Ù. ¸Åµ¶ ¿Ü¿¡µµ Àü½Å¼º È«¹Ý¼º ³¶Ã¢(SLE), ·ù¸¶ÅäÀÌµå °üÀý¿° µî¿¡¼­µµ ¾ç¼ºÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
    VDRL ¸é»ó ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
journal article The predominant publication type for articles and other items indexed for nlm databases.
(12 Dec 1998)
alpha interferon <cytokine> Interferon which is released by leukocytes in response to a viral infection. A protein cytokine that is used as an anticancer agent.
(15 Nov 1997)
antigen interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
beta interferon A protein liberated by fibroblasts in response to a viral infection.
(27 Sep 1997)
receptors, interferon Specific molecular sites or structures on or in cells with which interferons react or to which they bind in order to modify the function of the cells. Interferons exert their pleiotropic effects through two different receptors. Alpha- and beta-interferon crossreact with common receptors, while gamma-interferon initiates its biological effects through its own specific receptor system.
(12 Dec 1998)
immune interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
interferon <cytokine> A family of glycoproteins derived from human cells which normally has a role in fighting viral infections by preventing virus multiplication in cells.
They are secreted by vertebrate cells in response to a wide variety of inducers and confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions.
Interferon-alpha is made by leucocytes and interferon-gamma by fibroblasts after viral infection. Interferon-alpha and -beta are also called type I interferons, interferon-gamma as Type II interferons, more usually classed as cytokines.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
interferon-alpha <cytokine> One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products.
It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, causes activation of NK cells. It is used experimentally in the treatment of hairy-cell leukaemia.
A number of different subtypes exist that are elaborated by leukocytes in response to viral infection or stimulation with double-stranded RNA; IFN-alpha-2A and -2B are protein products made by recombinant DNA techniques and are used as antineoplastic agents.
See: interferon-alpha 2a, interferon-alpha 2b
Synonym: leukocyte interferon.
Pharmacological action: antineoplastic agent, antiviral agent.
(20 Sep 2002)
interferon-alpha 2a <cytokine> Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-alphaA (human leukocyte protein moiety reduced)
(12 Dec 1998)
interferon-alpha 2b <chemical> Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
interferon-b2 <cytokine> A cytokine that stimulates the growth and differentiation of human B-cells and is also a growth factor for hybridomas and plasmacytomas.
It is produced by many different cells including T-cells, monocytes, and fibroblasts. A single chain 25 kD cytokine originally described as a pre B-cell growth factor, now known to have effects on a number of other cells including T-cells which are also stimulated to proliferate.
An inducer of acute phase proteins and a colony-stimulating factor acting on mouse bone marrow.
Acronym: IL-6
(12 Dec 1998)
interferon-beta <cytokine> One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity.
Synonym: fibroblast interferon.
Pharmacological action: adjuvants, immunologic, antineoplastic agent, antiviral agents.
Chemical name: Interferon-alphaB (human leukocyte protein moiety reduced)
(12 Dec 1998)
interferon-gamma <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
interferon inducers Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers poly a-u and poly I-c. Viruses, bacteria, and protozoa have been also known to induce interferons.
(12 Dec 1998)
interferon type I <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • interferon
    ÀÎÅÍÆä·Ð(¹ÙÀÌ·¯½º Áõ½Ä ¾ïÁ¦ ¹°Áú)
  • journal
    Àϱâ
  • journal
    ÀÏÁö;Ç×ÇØ ÀÏÁö;ºÐ°³Àå;(Àϰ£)½Å¹®;(Á¤±â °£Çà)ÀâÁö;±¼´ëÀÇ ¸ñ;the Journals ±¹È¸ ÀÇ»ç·Ï
  • purchase journal
    ±¸ÀÔ ÀϰèÀå
  • research
    ¿¬±¸
  • listener research
    Àαâ ÇÁ·ÎÁ¶»ç
  • market research
    (Á¦Ç°À» ¸ÅÃâÇϱâ ÀüÀÇ) ½ÃÀå Á¶»ç
  • market research
    ½ÃÀå Á¶»ç (¾î¶² »óǰÀÇ ¼ö¿ä¸¦ À§ÇÑ »çÀü Á¶»ç)
  • marketing research
    ½ÃÀå Á¶»ç;½ÃÀå ºÐ¼®
  • motivational research
    µ¿±â Á¶»ç
  • operations research
    ±â¾÷ °æ¿µ»óÀÇ °úÇÐÀû Á¶»ç ¿¬±¸;ÀÛÀü ¿¬±¸
  • research
    (Çмú)¿¬±¸;°úÇÐÀû ޱ¸;ÇмúÁ¶»ç;(½ÅÁßÇÑ)¼ö»ö;ޱ¸;Á¶»ç;¿¬±¸ ´É·Â;¿¬±¸½É;¿¬±¸ÇÏ´Ù;Á¶»çÇÏ´Ù;~able
  • research and development
    ¿¬±¸¿Í °³¹ß
  • research laboratory(institute)
    ¿¬±¸¼Ò
  • research library
    ¿¬±¸ µµ¼­°ü ´Â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á